-Induction of CD28+ Memory T Cells and Decrease in Circulating Regulatory T Cells Correlate with PFS; No Safety Issues or Additive Toxicity of AGS-003 in Combination with Sunitinib- --Data Presented …
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
-Phase 2 Combination Study Demonstrates Decreases in T Regulatory Cells and Expansion of CD28+ Memory Cytotoxic T Lymphocytes (CTLs)- --Data Presented at 2011 ASCO Annual Meeting-- Durham, NC– June …
Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics´ Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
—In Vitro Results Published in Journal of Immunotherapy Demonstrate That Potency of Mature CD40L RNA Electroporated DCs Correlates with IL-12 Secretion by Tracking Multifunctional CD8(+)/CD28(+) …